Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biopharm Drug Dispos ; 36(7): 440-51, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25904312

RESUMEN

Apigenin (API) and luteolin (LUT) have been used as therapeutic agents in folk medicine for thousands of years. These compounds exert a variety of biological activities, including anticancer, antioxidant and antiinflammatory activities. This study investigated whether API and LUT could activate Nrf2-antioxidant response element (ARE)-mediated gene expression and induce antiinflammatory activities in human hepatoma HepG2 cells. The compounds did not exhibit any substantial toxicity at low doses (1.56-6.25 µm). The induction of ARE activity was assessed in HepG2-C8 cells after treatment with low doses of API and LUT for 6 and 12 h. It was found that the induction of ARE activity by these compounds at the higher doses was comparable to the effects of the positive control, SFN at a dose of 6.25 µm. Exposure to the PI3K inhibitor LY294002 abolished ARE activation by both API and LUT, whereas the ERK-1/2 inhibitor PD98059 only decreased ARE activity induced by API. Both compounds significantly increased the endogenous mRNA and protein levels of Nrf2 and Nrf2 target genes with important effects on heme oxygenase-1 (HO-1) expression. API and LUT significantly and dose-dependently decreased the production of nitric oxide (NO), nitric oxide synthase (iNOS) and cytosolic phospholipase A2 (cPLA2), which were induced by the treatment of HepG2 cells with 1 µg/ml of lipopolysaccharide (LPS) for 24 h. The results indicate that API and LUT significantly activate the PI3K/Nrf2/ARE system, and this activation may be responsible for their antiinflammatory effects, as demonstrated by the suppression of LPS-induced NO, iNOS and cPLA2.


Asunto(s)
Apigenina/farmacología , Flavonas/farmacología , Luteolina/farmacología , Factor 2 Relacionado con NF-E2/biosíntesis , Fitoquímicos/farmacología , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Relación Dosis-Respuesta a Droga , Regulación de la Expresión Génica , Células Hep G2 , Humanos , Factor 2 Relacionado con NF-E2/agonistas , Factor 2 Relacionado con NF-E2/genética
2.
Asian Pac J Cancer Prev ; 12(12): 3331-4, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22471475

RESUMEN

UNLABELLED: Numerous epidemiological studies suggest that frequent consumption of fish would decrease certain major inflammatory-related chronic diseases including cancer. AIMS: To investigate the cancer chemoprotective effect of fish oil (FO) in Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice fed a FO diet (10% Menhaden fish oil; FO group) versus a 20% high fat diet (HF group; typical of a Western diet), both with a total content of 20% fat and equal calories. METHODS: For each diet, two experimental arms were performed. The mice were put on diet at 8th or 12th week of age for periods of 14 and 10 weeks, the experiments being terminated when the mice reached 22 weeks of age. The animals were monitored weekly for health, and upon necropsy were examined for whole body metastasis, and prostate tissues were confirmed with histopathology. RESULTS: At the end of the study, the FO group had significantly reduced prostate tumor weight (p<0.05) compared to the HF group. The incidence of palpable tumors and carcinomas was also lowered. Finally, there was no metastasis found in the FO group, whereas in the HF group, 16.7% of the mice were found to have metastases. CONCLUSIONS: This is the first study showing the beneficial effects of FO against prostate cancer having a HF diet, suggesting potential beneficial effects of FO in humans consuming HF in their diet.


Asunto(s)
Adenocarcinoma/prevención & control , Dieta Alta en Grasa , Aceites de Pescado/uso terapéutico , Neoplasias de la Próstata/prevención & control , Adenocarcinoma/secundario , Animales , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Pronóstico , Neoplasias de la Próstata/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA